Application Data
(This assay recognizes recombinant Human DLL4. The factors listed above were prepared at 50ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.)
Human DLL4/Delta-like 4 ELISA Kit | DLL4 elisa kit
Human DLL4/Delta-like 4 ELISA Kit
Reactivity
Human
Synonyms
DLL4/Delta-like 4; N/A; Human DLL4/Delta-like 4 ELISA Kit; DLL4 ELISA Kit, Human; delta-like 4 (Drosophila); Delta-like 4 ELISA Kit, Human; hdelta2 ELISA Kit, Human; DLL4 elisa kit
Reactivity
Human
Specificity
The kit has been verified by high purity Human DLL4/Delta-like 4 recombinant protein.
Assay Type
Solid Phase Sandwich ELISA (quantitative)
Sample Types
Recombinant protein
Detection Range
36.1-2500pg/mL
Sensitivity
12.44pg/mL
Conjugation
HRP
Materials Provided
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
Application Data
(This assay recognizes recombinant Human DLL4. The factors listed above were prepared at 50ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.)
Application Data
(This assay recognizes recombinant Human DLL4. The factors listed above were prepared at 50ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.)
Standard Curve (Sample)
(This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.)
Standard Curve (Sample)
(This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.)
Related Product Information for DLL4 elisa kit
This DLL4 ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human DLL4 protein in Recombinant protein. It contains recombinant Human DLL4, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
Background: Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.
Background: Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.
References
Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis. Trends Mol Med. 13(9): 389-95.
Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis. Trends Mol Med. 13(9): 389-95.
Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
Similar Products
Product Notes
The Human DLL4 (Catalog #AAA258339) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. The AAA258339 ELISA Kit recognizes Human DLL4. It is sometimes possible for the material contained within the vial of "DLL4/Delta-like 4, ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.